METTL3 and bladder transitional cell carcinoma: (158) have designed a bidirectional deactivated RfxCas13d (dCasRx)-based m6A-editing platform that comprises the catalytic domains of METTL3 or ALKBH5 to manipulate the m6A demethylation of ITGA6 mRNA, thereby inhibiting BLCA cell growth.